Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005577 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine in Treating Children With Refractory Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00005577: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00005577 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005577, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of gemcitabine in treating children who have refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Interventions
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1996-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005577
The ClinicalTrials.gov registry entry for NCT00005577 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gemcitabine hydrochloride is the first listed.
NCT00005577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005577 about?
NCT00005577 is a clinical study titled "Gemcitabine in Treating Children With Refractory Solid Tumors". Phase I trial to study the effectiveness of gemcitabine in treating children who have refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00005577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1996-08.
What interventions are being tested in trial NCT00005577?
The interventions under investigation include: gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00005577?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.